GRF Grifols, S.A.
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
About Grifols (BME: GRF)
›
Grifols (BME: GRF) is listed on the Bolsa de Madrid, where its shares trade in EUR. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 25,000 employees.
The shares were at 11.07 EUR on 19 November 2026, up 9.1% over 52 weeks. Its 52-week range is 8.432 EUR to 11.73 EUR: the price is 5.6% below the high and 31.3% above the low.
At a market capitalisation of 7.53B EUR, it trades at 15.4 times trailing earnings and 10.1 times forward earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 26.0, a discount of 41% for GRF. It pays a dividend yielding 0.72% (it pays out 12% of its earnings), against a median of 2.43% among the dividend payers in that peer group.
Grifols reports return on equity of 7.6%, an operating margin of 18.9% and revenue up 9.4% year over year.
Its debt exceeds its cash by 8.75B EUR, a debt-to-equity ratio of 1.81. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 11 analysts cover the stock, with an average rating of Buy; their mean price target of 15.25 EUR is 37.8% above the current price. The next earnings report is expected on 25 February 2027.